A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. (3rd March 2016)

• Record Type: Journal Article
• Authors: O'Neil, B. H.; Scott, A. J.; Ma, W. W.; Cohen, S. J.; Aisner, D. L.; Menter, A. R.; Tejani, M. A.; Cho, J. K.; Granfortuna, J.; Coveler, A. L.; Olowokure, O. O.; Baranda, J. C.; Cusnir, M.; Phillip, P.; Boles, J.; Nazemzadeh, R.; Rarick, M.; Cohen, D. J.; Radford, J.; Fehrenbacher, L.; Bajaj, R.; Bathini, V.; Fanta, P.; Berlin, J.; McRee, A. J.; Maguire, R.; Wilhelm, F.; Maniar, M.; Jimeno, A.; Gomes, C. L.; Messersmith, W. A.;
• Is Part Of: Annals of oncology. Volume 27:Number 6(2016:Jun.)
• Page Start: 1180
• Page End: 1180
• Publication Date: 2016-03-03
• Subjects: Oncology -- Periodicals; 616.992
• DOI: 10.1093/annonc/mdw095
• Languages: English
• ISSNs: 0923-7534